Milan Mangeshkar
PhD
VP, Biometrics
Dr. Mangeshkar joined Zymeworks in January 2022 as Vice President, Biometrics. Dr. Mangeshkar brings 20+ years of experience providing oversight for all biostatics functions in multi-faceted health care organizations. Prior to joining Zymeworks Dr. Mangeshkar was at Exelixis Inc. for fourteen years where she was recognized for track record for leading successful Phase 1-4 oncology studies. Dr. Mangeshkar was a key contributor to four successful NDA/sNDA submissions to the FDA and EMA in indications that included medullary thyroid cancer, renal cell carcinoma, hepatocellular carcinoma. She has also worked in the diagnostics and devices areas. Dr. Mangeshkar holds a Ph.D. in Statistics from Virginia Tech and Master’s in Statistics from Bombay University.
Milan Mangeshkar
PhD
VP, Biometrics
Dr. Mangeshkar joined Zymeworks in January 2022 as Vice President, Biometrics. Dr. Mangeshkar brings 20+ years of experience providing oversight for all biostatics functions in multi-faceted health care organizations. Prior to joining Zymeworks Dr. Mangeshkar was at Exelixis Inc. for fourteen years where she was recognized for track record for leading successful Phase 1-4 oncology studies. Dr. Mangeshkar was a key contributor to four successful NDA/sNDA submissions to the FDA and EMA in indications that included medullary thyroid cancer, renal cell carcinoma, hepatocellular carcinoma. She has also worked in the diagnostics and devices areas. Dr. Mangeshkar holds a Ph.D. in Statistics from Virginia Tech and Master’s in Statistics from Bombay University.
Milan Mangeshkar
PhD
VP, Biometrics
Dr. Mangeshkar joined Zymeworks in January 2022 as Vice President, Biometrics. Dr. Mangeshkar brings 20+ years of experience providing oversight for all biostatics functions in multi-faceted health care organizations. Prior to joining Zymeworks Dr. Mangeshkar was at Exelixis Inc. for fourteen years where she was recognized for track record for leading successful Phase 1-4 oncology studies. Dr. Mangeshkar was a key contributor to four successful NDA/sNDA submissions to the FDA and EMA in indications that included medullary thyroid cancer, renal cell carcinoma, hepatocellular carcinoma. She has also worked in the diagnostics and devices areas. Dr. Mangeshkar holds a Ph.D. in Statistics from Virginia Tech and Master’s in Statistics from Bombay University.
Kaycia Wilde
PhD
VP, Clinical Operations
Dr. Wilde has served as VP of Clinical Operations since March 2021. Dr. Wilde is a global clinical research management professional with over 25 years’ experience in Clinical Development, including Oncology and the development of cell therapy products. Prior to joining Zymeworks, Dr. Wilde was SVP Operations at Kartos Therapeutics where she managed the Clinical Operations, Quality, CMC, Project Management and Facilities functions. Prior to that Dr. Wilde was head of Clinical Operations Europe at Kite Pharma where she built, developed, and managed EU Clinical Operations and Logistics teams through the development and successful European launch of Yescarta®. Dr. Wilde has also held various positions at AstraZeneca, Onyx Pharmaceuticals and Amgen working across multiple locations, therapeutic areas, indications and phases as well as heading up Amgen’s Global Development Operations Training, Quality and Standards team. Dr. Wilde received her BSc in Physiology and Ph.D. in Cardiac physiology from the University of Leeds, UK.
Kaycia Wilde
PhD
VP, Clinical Operations
Dr. Wilde has served as VP of Clinical Operations since March 2021. Dr. Wilde is a global clinical research management professional with over 25 years’ experience in Clinical Development, including Oncology and the development of cell therapy products. Prior to joining Zymeworks, Dr. Wilde was SVP Operations at Kartos Therapeutics where she managed the Clinical Operations, Quality, CMC, Project Management and Facilities functions. Prior to that Dr. Wilde was head of Clinical Operations Europe at Kite Pharma where she built, developed, and managed EU Clinical Operations and Logistics teams through the development and successful European launch of Yescarta®. Dr. Wilde has also held various positions at AstraZeneca, Onyx Pharmaceuticals and Amgen working across multiple locations, therapeutic areas, indications and phases as well as heading up Amgen’s Global Development Operations Training, Quality and Standards team. Dr. Wilde received her BSc in Physiology and Ph.D. in Cardiac physiology from the University of Leeds, UK.
Kaycia Wilde
PhD
VP, Clinical Operations
Dr. Wilde has served as VP of Clinical Operations since March 2021. Dr. Wilde is a global clinical research management professional with over 25 years’ experience in Clinical Development, including Oncology and the development of cell therapy products. Prior to joining Zymeworks, Dr. Wilde was SVP Operations at Kartos Therapeutics where she managed the Clinical Operations, Quality, CMC, Project Management and Facilities functions. Prior to that Dr. Wilde was head of Clinical Operations Europe at Kite Pharma where she built, developed, and managed EU Clinical Operations and Logistics teams through the development and successful European launch of Yescarta®. Dr. Wilde has also held various positions at AstraZeneca, Onyx Pharmaceuticals and Amgen working across multiple locations, therapeutic areas, indications and phases as well as heading up Amgen’s Global Development Operations Training, Quality and Standards team. Dr. Wilde received her BSc in Physiology and Ph.D. in Cardiac physiology from the University of Leeds, UK.
John Fann
PhD
VP, Technical Operations Process Science in Technical & Manufacturing Operations
Dr. Fann joins Zymeworks with over 20 years of experience in bioprocess development and biologics manufacturing and controls. Dr. Fann started his postdoctoral career with StemCell Technologies in Vancouver, then joined Seattle Genetics in its early years. After establishing the upstream function and accomplishing the first technology transfer and clinical manufacturing for Seagen, Dr. Fann joined AbbVie Bioresearch Center. He held several leadership positions in Process Sciences and MS&T. At AbbVie, Dr. Fann experienced many clinical projects and helped to launch and scale up several commercial biotherapeutics, including the blockbuster drug Humira. Dr. Fann joined Bristol Myers Squib after returning to Seattle, as the head of M&ST and Bioprocess Development. He was leading microbial process development at BMS and accomplished several early and late-stage clinical projects. Prior to Zymeworks, Dr. Fann was VP of Bioprocess R&D at AGC Biologics, leading the global new technology development at AGC. Dr. Fann holds a Ph.D. in Chemical Engineering from the University of British Columbia.
John Fann
PhD
VP, Technical Operations Process Science in Technical & Manufacturing Operations
Dr. Fann joins Zymeworks with over 20 years of experience in bioprocess development and biologics manufacturing and controls. Dr. Fann started his postdoctoral career with StemCell Technologies in Vancouver, then joined Seattle Genetics in its early years. After establishing the upstream function and accomplishing the first technology transfer and clinical manufacturing for Seagen, Dr. Fann joined AbbVie Bioresearch Center. He held several leadership positions in Process Sciences and MS&T. At AbbVie, Dr. Fann experienced many clinical projects and helped to launch and scale up several commercial biotherapeutics, including the blockbuster drug Humira. Dr. Fann joined Bristol Myers Squib after returning to Seattle, as the head of M&ST and Bioprocess Development. He was leading microbial process development at BMS and accomplished several early and late-stage clinical projects. Prior to Zymeworks, Dr. Fann was VP of Bioprocess R&D at AGC Biologics, leading the global new technology development at AGC. Dr. Fann holds a Ph.D. in Chemical Engineering from the University of British Columbia.
John Fann
PhD
VP, Technical Operations Process Science in Technical & Manufacturing Operations
Dr. Fann joins Zymeworks with over 20 years of experience in bioprocess development and biologics manufacturing and controls. Dr. Fann started his postdoctoral career with StemCell Technologies in Vancouver, then joined Seattle Genetics in its early years. After establishing the upstream function and accomplishing the first technology transfer and clinical manufacturing for Seagen, Dr. Fann joined AbbVie Bioresearch Center. He held several leadership positions in Process Sciences and MS&T. At AbbVie, Dr. Fann experienced many clinical projects and helped to launch and scale up several commercial biotherapeutics, including the blockbuster drug Humira. Dr. Fann joined Bristol Myers Squib after returning to Seattle, as the head of M&ST and Bioprocess Development. He was leading microbial process development at BMS and accomplished several early and late-stage clinical projects. Prior to Zymeworks, Dr. Fann was VP of Bioprocess R&D at AGC Biologics, leading the global new technology development at AGC. Dr. Fann holds a Ph.D. in Chemical Engineering from the University of British Columbia.
Mark Hollywood
Executive Vice President and Head of Technical and Manufacturing Operations
Mr. Hollywood joined Zymeworks in 2019 and currently serves as our Executive Vice President and Head of Technical and Manufacturing Operations. Mr. Hollywood brings over 25 years of experience in the biopharmaceutical industry, most recently as Vice President and Head of ZymoGenetics (a Bristol-Myers Squibb company), where he oversaw biologics development, manufacturing, quality, and supply chain operations. He joined ZymoGenetics in 2010 and led technical operations for a portfolio of clinical and commercial products, and was responsible for building and managing a multi-host drug substance manufacturing facility. Mr. Hollywood brings a wealth of experience in operations management, having held positions of increasing responsibility in process science, manufacturing, quality, and regulatory compliance at organizations including Amgen, Dendreon and Centeon (a Rhone-Poulenc Rorer and Hoescht company). Mr. Hollywood has a Bachelor of Science degree in Biological Sciences from Western Illinois University.
Mark Hollywood
Executive Vice President and Head of Technical and Manufacturing Operations
Mr. Hollywood joined Zymeworks in 2019 and currently serves as our Executive Vice President and Head of Technical and Manufacturing Operations. Mr. Hollywood brings over 25 years of experience in the biopharmaceutical industry, most recently as Vice President and Head of ZymoGenetics (a Bristol-Myers Squibb company), where he oversaw biologics development, manufacturing, quality, and supply chain operations. He joined ZymoGenetics in 2010 and led technical operations for a portfolio of clinical and commercial products, and was responsible for building and managing a multi-host drug substance manufacturing facility. Mr. Hollywood brings a wealth of experience in operations management, having held positions of increasing responsibility in process science, manufacturing, quality, and regulatory compliance at organizations including Amgen, Dendreon and Centeon (a Rhone-Poulenc Rorer and Hoescht company). Mr. Hollywood has a Bachelor of Science degree in Biological Sciences from Western Illinois University.
Mark Hollywood
Executive Vice President and Head of Technical and Manufacturing Operations
Mr. Hollywood joined Zymeworks in 2019 and currently serves as our Executive Vice President and Head of Technical and Manufacturing Operations. Mr. Hollywood brings over 25 years of experience in the biopharmaceutical industry, most recently as Vice President and Head of ZymoGenetics (a Bristol-Myers Squibb company), where he oversaw biologics development, manufacturing, quality, and supply chain operations. He joined ZymoGenetics in 2010 and led technical operations for a portfolio of clinical and commercial products, and was responsible for building and managing a multi-host drug substance manufacturing facility. Mr. Hollywood brings a wealth of experience in operations management, having held positions of increasing responsibility in process science, manufacturing, quality, and regulatory compliance at organizations including Amgen, Dendreon and Centeon (a Rhone-Poulenc Rorer and Hoescht company). Mr. Hollywood has a Bachelor of Science degree in Biological Sciences from Western Illinois University.
Chris Astle
PhD
SVP & Chief Financial Officer
Dr. Astle joined Zymeworks in April 2021 and currently serves as Senior Vice President and Chief Financial Officer. Prior to joining Zymeworks, Dr. Astle worked as a Chief Financial Officer at the CFO Centre in British Columbia, Canada from March 2020 to March 2021, and as Vice President, Finance at Alder BioPharmaceuticals Inc. in Seattle, Washington from April 2019 to February 2020. From August 2017 to January 2020, he served as Chief Executive Officer and founder of Think Forwards, a boutique financial consulting firm in London, UK. Dr. Astle worked at Allergan from 2011 to 2017, including as the Associate Vice President Finance, International Division from July 2016 to July 2017, managing multiple product launches, M&A transactions and restructurings, with a team of 170 across 60 countries. He is a UK Chartered Accountant (ICAS), qualifying at PwC London, UK in Audit & Pharmaceutical Performance Improvement Consulting with audit clients including GSK. Dr. Astle serves as a member of the board of directors of two private biotechnology companies, Oak Bay Biosciences (2020-present) and Healome Therapeutics (2021-present). During his time in the UK, he was the Chair of the 2018 CFO Agenda conference, guest lecturer at the Henley Business School, and judge at the British Accountancy Awards. Dr. Astle holds a PhD in Organic Chemistry from the University of Bristol (UK) and a MChem in Chemistry from the University of Liverpool (UK) and is also a certified ski instructor.
Chris Astle
PhD
SVP & Chief Financial Officer
Dr. Astle joined Zymeworks in April 2021 and currently serves as Senior Vice President and Chief Financial Officer. Prior to joining Zymeworks, Dr. Astle worked as a Chief Financial Officer at the CFO Centre in British Columbia, Canada from March 2020 to March 2021, and as Vice President, Finance at Alder BioPharmaceuticals Inc. in Seattle, Washington from April 2019 to February 2020. From August 2017 to January 2020, he served as Chief Executive Officer and founder of Think Forwards, a boutique financial consulting firm in London, UK. Dr. Astle worked at Allergan from 2011 to 2017, including as the Associate Vice President Finance, International Division from July 2016 to July 2017, managing multiple product launches, M&A transactions and restructurings, with a team of 170 across 60 countries. He is a UK Chartered Accountant (ICAS), qualifying at PwC London, UK in Audit & Pharmaceutical Performance Improvement Consulting with audit clients including GSK. Dr. Astle serves as a member of the board of directors of two private biotechnology companies, Oak Bay Biosciences (2020-present) and Healome Therapeutics (2021-present). During his time in the UK, he was the Chair of the 2018 CFO Agenda conference, guest lecturer at the Henley Business School, and judge at the British Accountancy Awards. Dr. Astle holds a PhD in Organic Chemistry from the University of Bristol (UK) and a MChem in Chemistry from the University of Liverpool (UK) and is also a certified ski instructor.
Chris Astle
PhD
SVP & Chief Financial Officer
Dr. Astle joined Zymeworks in April 2021 and currently serves as Senior Vice President and Chief Financial Officer. Prior to joining Zymeworks, Dr. Astle worked as a Chief Financial Officer at the CFO Centre in British Columbia, Canada from March 2020 to March 2021, and as Vice President, Finance at Alder BioPharmaceuticals Inc. in Seattle, Washington from April 2019 to February 2020. From August 2017 to January 2020, he served as Chief Executive Officer and founder of Think Forwards, a boutique financial consulting firm in London, UK. Dr. Astle worked at Allergan from 2011 to 2017, including as the Associate Vice President Finance, International Division from July 2016 to July 2017, managing multiple product launches, M&A transactions and restructurings, with a team of 170 across 60 countries. He is a UK Chartered Accountant (ICAS), qualifying at PwC London, UK in Audit & Pharmaceutical Performance Improvement Consulting with audit clients including GSK. Dr. Astle serves as a member of the board of directors of two private biotechnology companies, Oak Bay Biosciences (2020-present) and Healome Therapeutics (2021-present). During his time in the UK, he was the Chair of the 2018 CFO Agenda conference, guest lecturer at the Henley Business School, and judge at the British Accountancy Awards. Dr. Astle holds a PhD in Organic Chemistry from the University of Bristol (UK) and a MChem in Chemistry from the University of Liverpool (UK) and is also a certified ski instructor.
Jeffrey Smith
MD, FRCP
SVP, Early-Stage Development
Dr. Smith joined Zymeworks in January 2023 and currently serves as our Senior Vice President of Early-Stage Development based at our European hub in Dublin, Ireland . Dr. Smith has held many senior positions within the pharmaceutical industry, most recently, Managing Director of Alder Biopharmaceuticals Inc. Dublin, Ireland and before that Senior Vice President, Translational Medicine at Alder Biopharmaceuticals Inc, Seattle. Dr. Smith was responsible for the clinical development (phase I – III) of eptinezumab (anti-CGRP antibody for migraine) and clazakizumab (anti -IL-6 antibody for rheumatoid arthritis and cancer cachexia). Dr. Smith was also a founder of Alder Biopharmaceutcials Inc (founded 2004). Dr. Smith received his MB BS and MD from the University of London, UK.

Jeffrey Smith
MD, FRCP
SVP, Early-Stage Development
Dr. Smith joined Zymeworks in January 2023 and currently serves as our Senior Vice President of Early-Stage Development based at our European hub in Dublin, Ireland . Dr. Smith has held many senior positions within the pharmaceutical industry, most recently, Managing Director of Alder Biopharmaceuticals Inc. Dublin, Ireland and before that Senior Vice President, Translational Medicine at Alder Biopharmaceuticals Inc, Seattle. Dr. Smith was responsible for the clinical development (phase I – III) of eptinezumab (anti-CGRP antibody for migraine) and clazakizumab (anti -IL-6 antibody for rheumatoid arthritis and cancer cachexia). Dr. Smith was also a founder of Alder Biopharmaceutcials Inc (founded 2004). Dr. Smith received his MB BS and MD from the University of London, UK.

Jeffrey Smith
MD, FRCP
SVP, Early-Stage Development
Dr. Smith joined Zymeworks in January 2023 and currently serves as our Senior Vice President of Early-Stage Development based at our European hub in Dublin, Ireland . Dr. Smith has held many senior positions within the pharmaceutical industry, most recently, Managing Director of Alder Biopharmaceuticals Inc. Dublin, Ireland and before that Senior Vice President, Translational Medicine at Alder Biopharmaceuticals Inc, Seattle. Dr. Smith was responsible for the clinical development (phase I – III) of eptinezumab (anti-CGRP antibody for migraine) and clazakizumab (anti -IL-6 antibody for rheumatoid arthritis and cancer cachexia). Dr. Smith was also a founder of Alder Biopharmaceutcials Inc (founded 2004). Dr. Smith received his MB BS and MD from the University of London, UK.

Daniel Dex
JD
SVP, Corporate Secretary and General Counsel
Mr. Dex joined Zymeworks in September 2017, and currently serves as our Senior Vice President, Corporate Secretary and General Counsel. Mr. Dex brings over 25 years of diverse legal experience to Zymeworks, having worked in private practice at prominent law firms in both the U.S. and Canada, in-house with Avigilon Corporation (a Motorola Solutions company) and the New York Public Library, and with the U.S. federal district court for the Eastern District of Pennsylvania. Mr. Dex received a J.D. from the University of Pennsylvania Law School and a B.A. from Brown University. He is a member of the bars of both New York and British Columbia.
Daniel Dex
JD
SVP, Corporate Secretary and General Counsel
Mr. Dex joined Zymeworks in September 2017, and currently serves as our Senior Vice President, Corporate Secretary and General Counsel. Mr. Dex brings over 25 years of diverse legal experience to Zymeworks, having worked in private practice at prominent law firms in both the U.S. and Canada, in-house with Avigilon Corporation (a Motorola Solutions company) and the New York Public Library, and with the U.S. federal district court for the Eastern District of Pennsylvania. Mr. Dex received a J.D. from the University of Pennsylvania Law School and a B.A. from Brown University. He is a member of the bars of both New York and British Columbia.
Daniel Dex
JD
SVP, Corporate Secretary and General Counsel
Mr. Dex joined Zymeworks in September 2017, and currently serves as our Senior Vice President, Corporate Secretary and General Counsel. Mr. Dex brings over 25 years of diverse legal experience to Zymeworks, having worked in private practice at prominent law firms in both the U.S. and Canada, in-house with Avigilon Corporation (a Motorola Solutions company) and the New York Public Library, and with the U.S. federal district court for the Eastern District of Pennsylvania. Mr. Dex received a J.D. from the University of Pennsylvania Law School and a B.A. from Brown University. He is a member of the bars of both New York and British Columbia.
Paul Moore
PhD
Chief Scientific Officer
Dr. Moore joined Zymeworks in July 2022 and currently serves as our Chief Scientific Officer. Dr. Moore brings over 25 years of US-based experience in biologics drug discovery and development in biotechnology research. His career efforts have led to the discovery and development of a range of FDA-approved and clinical-stage biologics for patients with difficult-to-treat cancers and autoimmune conditions. Prior to joining Zymeworks, Paul served as Vice President, Cell Biology, and Immunology at MacroGenics, where he worked on the development of numerous clinical stage compounds and scientific collaborations with a range of pharmaceutical partners, including Pfizer, Servier, Gilead, Takeda, Janssen, Roche and Zai Labs. Prior to joining MacroGenics, he was Director of Cell Biology at Celera where he oversaw research efforts to develop novel antibody-based therapeutics. Dr. Moore received a Ph.D. in molecular genetics from the University of Glasgow. He has an extensive research record co-authoring over 75 peer-reviewed manuscripts and is a named co-inventor on over 50 issued US patents.
Paul Moore
PhD
Chief Scientific Officer
Dr. Moore joined Zymeworks in July 2022 and currently serves as our Chief Scientific Officer. Dr. Moore brings over 25 years of US-based experience in biologics drug discovery and development in biotechnology research. His career efforts have led to the discovery and development of a range of FDA-approved and clinical-stage biologics for patients with difficult-to-treat cancers and autoimmune conditions. Prior to joining Zymeworks, Paul served as Vice President, Cell Biology, and Immunology at MacroGenics, where he worked on the development of numerous clinical stage compounds and scientific collaborations with a range of pharmaceutical partners, including Pfizer, Servier, Gilead, Takeda, Janssen, Roche and Zai Labs. Prior to joining MacroGenics, he was Director of Cell Biology at Celera where he oversaw research efforts to develop novel antibody-based therapeutics. Dr. Moore received a Ph.D. in molecular genetics from the University of Glasgow. He has an extensive research record co-authoring over 75 peer-reviewed manuscripts and is a named co-inventor on over 50 issued US patents.
Paul Moore
PhD
Chief Scientific Officer
Dr. Moore joined Zymeworks in July 2022 and currently serves as our Chief Scientific Officer. Dr. Moore brings over 25 years of US-based experience in biologics drug discovery and development in biotechnology research. His career efforts have led to the discovery and development of a range of FDA-approved and clinical-stage biologics for patients with difficult-to-treat cancers and autoimmune conditions. Prior to joining Zymeworks, Paul served as Vice President, Cell Biology, and Immunology at MacroGenics, where he worked on the development of numerous clinical stage compounds and scientific collaborations with a range of pharmaceutical partners, including Pfizer, Servier, Gilead, Takeda, Janssen, Roche and Zai Labs. Prior to joining MacroGenics, he was Director of Cell Biology at Celera where he oversaw research efforts to develop novel antibody-based therapeutics. Dr. Moore received a Ph.D. in molecular genetics from the University of Glasgow. He has an extensive research record co-authoring over 75 peer-reviewed manuscripts and is a named co-inventor on over 50 issued US patents.
Neil Klompas
CPA, CA
President and Chief Operating Officer
Mr. Klompas joined Zymeworks in March 2007 and currently serves as our President and Chief Operating Officer. Mr. Klompas served as Zymeworks’ Chief Financial Officer from 2007 to 2022. Prior to joining Zymeworks, he worked with KPMG LLP in Canada and the United States, most recently (from 2005 to 2007) with KPMG’s Pharmaceuticals, Biotechnology and Medical Device M&A Transaction Services practice in Princeton, New Jersey, where he advised on transactions including mergers, acquisitions, divestitures and strategic alliances. Prior to that, from 2000 to 2005 Mr. Klompas worked with KPMG’s Canadian Biotechnology and Pharmaceuticals practice. Mr. Klompas currently serves on the board of directors of Liminal BioSciences Inc. (NASDAQ: LMNL). Mr. Klompas is a Chartered Professional Accountant and is a member of the Chartered Professional Accountants of British Columbia. Mr. Klompas also holds a degree in Microbiology & Immunology from the University of British Columbia
Neil Klompas
CPA, CA
President and Chief Operating Officer
Mr. Klompas joined Zymeworks in March 2007 and currently serves as our President and Chief Operating Officer. Mr. Klompas served as Zymeworks’ Chief Financial Officer from 2007 to 2022. Prior to joining Zymeworks, he worked with KPMG LLP in Canada and the United States, most recently (from 2005 to 2007) with KPMG’s Pharmaceuticals, Biotechnology and Medical Device M&A Transaction Services practice in Princeton, New Jersey, where he advised on transactions including mergers, acquisitions, divestitures and strategic alliances. Prior to that, from 2000 to 2005 Mr. Klompas worked with KPMG’s Canadian Biotechnology and Pharmaceuticals practice. Mr. Klompas currently serves on the board of directors of Liminal BioSciences Inc. (NASDAQ: LMNL). Mr. Klompas is a Chartered Professional Accountant and is a member of the Chartered Professional Accountants of British Columbia. Mr. Klompas also holds a degree in Microbiology & Immunology from the University of British Columbia
Neil Klompas
CPA, CA
President and Chief Operating Officer
Mr. Klompas joined Zymeworks in March 2007 and currently serves as our President and Chief Operating Officer. Mr. Klompas served as Zymeworks’ Chief Financial Officer from 2007 to 2022. Prior to joining Zymeworks, he worked with KPMG LLP in Canada and the United States, most recently (from 2005 to 2007) with KPMG’s Pharmaceuticals, Biotechnology and Medical Device M&A Transaction Services practice in Princeton, New Jersey, where he advised on transactions including mergers, acquisitions, divestitures and strategic alliances. Prior to that, from 2000 to 2005 Mr. Klompas worked with KPMG’s Canadian Biotechnology and Pharmaceuticals practice. Mr. Klompas currently serves on the board of directors of Liminal BioSciences Inc. (NASDAQ: LMNL). Mr. Klompas is a Chartered Professional Accountant and is a member of the Chartered Professional Accountants of British Columbia. Mr. Klompas also holds a degree in Microbiology & Immunology from the University of British Columbia
Kenneth Galbraith
Chair & CEO
Mr. Galbraith has served as Zymeworks’ Chair & CEO since January 2022. Mr. Galbraith has over 35 years’ experience in biotechnology and venture capital having acted as an executive, director, investor as well as an advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors across North America and the UK in the growth of both private and public companies from an early-stage through regulatory approval and commercialization. Ken has worked with many biotechnology companies including: Macrogenics, AnorMED, Alder Pharmaceuticals, Celator Pharmaceuticals, Novadaq, Profound Medical, Fairhaven Pharmaceuticals, Tekmira, Angiotech, Aquinox, and Xenon Pharmaceuticals among others. Mr. Galbraith currently serves on the board of directors of Profound Medical and Kalium Health. He earned a Bachelor of Commerce (Honors) degree from the University of British Columbia in 1985.
Kenneth Galbraith
Chair & CEO
Mr. Galbraith has served as Zymeworks’ Chair & CEO since January 2022. Mr. Galbraith has over 35 years’ experience in biotechnology and venture capital having acted as an executive, director, investor as well as an advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors across North America and the UK in the growth of both private and public companies from an early-stage through regulatory approval and commercialization. Ken has worked with many biotechnology companies including: Macrogenics, AnorMED, Alder Pharmaceuticals, Celator Pharmaceuticals, Novadaq, Profound Medical, Fairhaven Pharmaceuticals, Tekmira, Angiotech, Aquinox, and Xenon Pharmaceuticals among others. Mr. Galbraith currently serves on the board of directors of Profound Medical and Kalium Health. He earned a Bachelor of Commerce (Honors) degree from the University of British Columbia in 1985.
Kenneth Galbraith
Chair & CEO
Mr. Galbraith has served as Zymeworks’ Chair & CEO since January 2022. Mr. Galbraith has over 35 years’ experience in biotechnology and venture capital having acted as an executive, director, investor as well as an advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors across North America and the UK in the growth of both private and public companies from an early-stage through regulatory approval and commercialization. Ken has worked with many biotechnology companies including: Macrogenics, AnorMED, Alder Pharmaceuticals, Celator Pharmaceuticals, Novadaq, Profound Medical, Fairhaven Pharmaceuticals, Tekmira, Angiotech, Aquinox, and Xenon Pharmaceuticals among others. Mr. Galbraith currently serves on the board of directors of Profound Medical and Kalium Health. He earned a Bachelor of Commerce (Honors) degree from the University of British Columbia in 1985.